Results 191 to 200 of about 35,648 (268)

Critical analysis of compositions and protective efficacies of oral killed cholera vaccines. [PDF]

Clin Vaccine Immunol, 2014
Kabir S.
europepmc   +1 more source

NKp46+ Innate Lymphoid Cells Dampen Vaginal CD8 T Cell Responses following Local Immunization with a Cholera Toxin-Based Vaccine

, 2015
Carmelo Luci, Selma Bekri, Franck Bihl, Jonathan Pini, Pierre Bourdely, Kelly Nouhen, Angélique Malgogne, Thierry Walzer, Véronique M. Braud, Fabienne Anjuère   +9 more
openalex   +2 more sources

Addressing the Recurrent and Protracted Cholera Outbreaks in Africa: Challenges and the Way Forward. [PDF]

Nat Commun
Dereje N, Aragaw M, Mercy K, Moges H, Shaweno T, Tsague LD, Tanui C, Kifle Tessema S, Raji T, Boum Y, Fallah MP, Ngongo N, Kaseya J.   +12 more
europepmc   +1 more source

Cholera surveillance time series in Africa between 2010 and 2023. [PDF]

Gates Open Res
Zheng Q, DePencier R, Demby MN, Azman AS, Lee EC.   +4 more
europepmc   +1 more source

Prioritisation and risk ranking of epidemic-prone diseases for emergency preparedness and response in Eastern Africa using a multi-criteria decision analysis framework, 2023. [PDF]

J Public Health Afr
Kamara N, Guyassa M, Theocharopoulos G, Mohamed AS, Said HM, Pampaka D, Suk J, Riek LP, Aragaw M.   +8 more
europepmc   +1 more source

Cholera Vaccine Inactivated Oral

Drugs in R & D, 1999
openaire   +2 more sources

Effectiveness of a reactive oral cholera vaccination during a cholera outbreak at the Douala New-Bell Central Prison in Cameroon. [PDF]

PLoS Negl Trop Dis
Bekolo CE, Wetie Tchakoutio PL, Endalle Esso L, Ewane L, Ateudjieu J.   +4 more
europepmc   +1 more source

Molecular characterization of positive-stranded RNA viruses [PDF]

, 1993
Conzelmann, Karl-Klaus, Kaaden, Oskar-Rüger, Meyers, G., Rümenapf, T., Stark, R., Tautz, N., Thiel, Heinz-Jürgen, Unger, G.   +7 more
core  

Public health round-up. [PDF]

Bull World Health Organ
europepmc   +1 more source

Serological responses to killed oral cholera vaccine (OCV) when given 4 years after initial receipt of OCV in Cameroon: A randomized controlled trial. [PDF]

PLOS Glob Public Health
Ateudjieu J, Tchio-Nighie KH, Guenou E, Fokou C, Buh Nkum C, Beyala Bita'a L, Ateudjieu-Kenfack WD, Nanfak S, Debes AK, Sack DA.   +9 more
europepmc   +1 more source